Mindikoglu, Ayse L. http://orcid.org/0000-0003-4598-8692
Opekun, Antone R.
Mitch, William E.
Magder, Laurence S.
Christenson, Robert H.
Dowling, Thomas C.
Weir, Matthew R.
Seliger, Stephen L.
Howell, Charles D.
Raufman, Jean-Pierre
Rana, Abbas
Goss, John A.
Khaderi, Saira A.
Vierling, John M.
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (5 K23 DK089008-05)
University of Maryland School of Medicine
National Institutes of Health (P30 DK056338)
Article History
Received: 18 September 2017
Accepted: 21 December 2017
First Online: 1 February 2018
Compliance with ethical standards
:
: Ayse L. Mindikoglu, M.D., M.P.H. A provisional patent application (Serial No: 62/442,479) is filed with the US patent office on 01/05/2017 (Metabolomic Markers to Predict Mortality in Patients with Cirrhosis). A second provisional patent application (Serial No. 62/586,966) is filed with the US Patent and Trademark Office on November 16, 2017, entitled “Metabolomic Biomarkers of Hepatorenal Dysfunction and Mortality in Patients with Cirrhosis.” John M. Vierling, M.D. received research grant support from Mallinckrodt for studies of terlipressin in hepatorenal syndrome.
: Mindikoglu AL, Opekun AR, Mitch WE, Magder LS, Christenson RH, Dowling TC, Weir MR, Seliger SL, Howell CD, Raufman, JP, Rana A, Goss JA, Sussman NL, Vierling JM. Serum Creatinine in Female Patients with Cirrhosis Unfairly Bias Liver Transplant Wait List Ranking: Implications for Elimination of Gender Disparities in Access to Orthotopic Liver Transplantation. Gastroenterology 2017;152:5, S1120 (Abstract selected as a Poster of Distinction for presentation during Digestive Disease Week<sup>®</sup> at McCormick Place in Chicago, IL, May 6–9, 2017).